Biotech · Private company
BioLineRx, Ltd.
Track this companyFree. Adds BioLineRx, Ltd. to your Dealase workspace and tells you when its record changes.
Clinical trials101 recruiting or active
Pipeline programs13From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline13
- BL-8040 1.25 mg/kg + G-CSFPhase 3 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- Ara-CPhase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- AtezolizumabPhase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- BL-8040Phase 2 · Metastatic Pancreatic AdenocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- BL-8040Phase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- BL-8040Phase 2 · Aplastic AnemiaClinicalTrials.gov · fetched Nov 12, 2026
- ChemotherapyPhase 2 · Metastatic Pancreatic AdenocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- CyclosporinePhase 2 · Aplastic AnemiaClinicalTrials.gov · fetched Nov 12, 2026
- horse anti-thymocyte globulin (hATG)Phase 2 · Aplastic AnemiaClinicalTrials.gov · fetched Nov 12, 2026
- MethylprednisolonePhase 2 · Aplastic AnemiaClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Metastatic Pancreatic AdenocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- 2 mg/kg BL-8040Phase 1 · Healthy SubjectsClinicalTrials.gov · fetched Nov 12, 2026
- 400 mg Moxifloxacin (1x400 mg tablet)Phase 1 · Healthy SubjectsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials10
- A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF MobilizationPHASE1 · COMPLETED · started Oct 31, 2024ClinicalTrials.gov NCT06547112 · fetched Nov 12, 2026
- Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)PHASE1 · COMPLETED · started Jul 7, 2023ClinicalTrials.gov NCT05618301 · fetched Nov 12, 2026
- Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy SubjectsPHASE1 · COMPLETED · started Jun 11, 2021ClinicalTrials.gov NCT05293171 · fetched Nov 12, 2026
- A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)PHASE3 · ACTIVE_NOT_RECRUITING · started Mar 23, 2018ClinicalTrials.gov NCT03246529 · fetched Nov 12, 2026
- Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML)PHASE1_PHASE2 · TERMINATED · started Jan 8, 2018ClinicalTrials.gov NCT03154827 · fetched Nov 12, 2026
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)PHASE1_PHASE2 · TERMINATED · started Oct 13, 2017ClinicalTrials.gov NCT03281369 · fetched Nov 12, 2026
- Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer PatientsPHASE2 · COMPLETED · started Sep 1, 2016ClinicalTrials.gov NCT02826486 · fetched Nov 12, 2026
- Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological MalignanciesPHASE2 · COMPLETED · started Mar 31, 2016ClinicalTrials.gov NCT02639559 · fetched Nov 12, 2026
- Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic SyndromePHASE2 · COMPLETED · started Oct 1, 2015ClinicalTrials.gov NCT02462252 · fetched Nov 12, 2026
- Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML PatientsPHASE2 · COMPLETED · started Apr 1, 2013ClinicalTrials.gov NCT01838395 · fetched Nov 12, 2026